Effect of miR-146a polymorphism on biochemical recurrence risk after radical prostatectomy in southern Chinese population

Genetics and Molecular Research

Volumn 13, Issue 4, 2014, Pages 10615-10621

  Chen, M ^a,b   Zhou, Z Y ^c   Chen, J G ^d   Tong, N ^e   Chen, S Q ^a   Yang, Y ^a   Zhang, X W ^a   Jiang, H ^a   Liu, N ^a   Liu, J ^a   Sha, G Z ^a   Zhu, W D ^a   Hua, L X ^f   Wang, Z J ^f   Xu, B ^a,b  

^a AFFILIATED ZHONGDA HOSPITAL OF SOUTHEAST UNIVERSITY   (China)

^b MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

^c Departments of Neurosurgery The First People s Hospital of Suqian   (China)

^d NANTONG UNIVERSITY   (China)

^e NANJING MEDICAL UNIVERSITY   (China)

^f THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Biochemical recurrence; miR 146a; Polymorphism; Prostate cancer

Indexed keywords

MICRORNA 146A; PROSTATE SPECIFIC ANTIGEN; MICRORNA; MIRN146 MICRORNA, HUMAN;

AGED; ARTICLE; BIOCHEMICAL RECURRENCE FREE SURVIVAL; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CHINESE; GENETIC POLYMORPHISM; GENOTYPE; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PERINEURAL INVASION; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY; CHINA; GENETICS; METABOLISM; PROGNOSIS; PROSTATIC NEOPLASMS; RECURRENT DISEASE; RISK FACTOR; STATISTICS AND NUMERICAL DATA;

AGED; CHINA; HUMANS; MALE; MICRORNAS; POLYMORPHISM, GENETIC; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECURRENCE; RISK FACTORS;

EID: 84919360477     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/2014.December.18.3     Document Type: Article

References (14)

1. Amiel J, de Pontual L and Henrion-Caude A (2012). miRNA, development and disease. Adv. Genet. 80: 1-36.
2. Beheshti M, Haim S, Zakavi R, Steinmair M, et al. (2013). Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics. J. Nucl. Med. 54: 833-840.
3. Bhaumik D, Scott GK, Schokrpur S, Patil CK, et al. (2008). Expression of microRNA-146 suppresses NF-kappaB activity with reduction of metastatic potential in breast cancer cells. Oncogene 27: 5643-5647.
4. Guan X, Sturgis EM, Song X, Liu Z, et al. (2013). Pre-microRNA variants predict HPV16-positive tumors and survival in patients with squamous cell carcinoma of the oropharynx. Cancer Lett. 330: 233-240.
5. Labbaye C and Testa U (2012). The emerging role of MIR-146A in the control of hematopoiesis, immune function and cancer. J. Hematol. Oncol. 5: 13.
6. Li Y, Vandenboom TG, Wang Z, Kong D, et al. (2010). miR-146a suppresses invasion of pancreatic cancer cells. Cancer Res. 70: 1486-1495.
7. Lin SL, Chiang A, Chang D and Ying SY (2008). Loss of mir-146a function in hormone-refractory prostate cancer. RNA 14: 417-424.
8. Permuth-Wey J, Thompson RC, Burton NL, Olson JJ, et al. (2011). A functional polymorphism in the pre-miR-146a gene is associated with risk and prognosis in adult glioma. J. Neurooncol. 105: 639-646.
9. Roberts WB and Han M (2009). Clinical significance and treatment of biochemical recurrence after definitive therapy for localized prostate cancer. Surg. Oncol. 18: 268-274.
10. Siegel R, Naishadham D and Jemal A (2013). Cancer statistics, 2013. CA Cancer J. Clin. 63: 11-30.
11. Wang M, Chu H, Li P, Yuan L, et al. (2012). Genetic variants in miRNAs predict bladder cancer risk and recurrence. Cancer Res. 72: 6173-6182.
12. Wu K, Liu J, Tseng SF, Gore C, et al. (2014). The role of DAB2IP in androgen receptor activation during prostate cancer progression. Oncogene 33: 1954-1963.
13. Xu B, Feng NH, Li PC, Tao J, et al. (2010). A functional polymorphism in Pre-miR-146a gene is associated with prostate cancer risk and mature miR-146a expression in vivo. Prostate 70: 467-472.
14. Xu B, Wang N, Wang X, Tong N, et al. (2012). miR-146a suppresses tumor growth and progression by targeting EGFR pathway and in a p-ERK-dependent manner in castration-resistant prostate cancer. Prostate 72: 1171-1178.